Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for PGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -17.81M
March 31, 2026 -43.83M
December 31, 2025 -23.46M
September 30, 2025 -29.07M
June 30, 2025 -18.98M
March 31, 2025 -16.32M
December 31, 2024 -8.243M
September 30, 2024 -22.73M
June 30, 2024 -23.11M
March 31, 2024 -14.09M
December 31, 2023 -15.77M
September 30, 2023 -17.01M
June 30, 2023 -15.77M
March 31, 2023 -18.39M
December 31, 2022 -15.40M
September 30, 2022 -23.81M
June 30, 2022 -7.053M
March 31, 2022 -18.78M
December 31, 2021 -14.59M
September 30, 2021 -17.02M
June 30, 2021 -7.776M
March 31, 2021 -16.38M
December 31, 2020 -16.47M
September 30, 2020 -19.00M
June 30, 2020 -13.80M
Date Value
March 31, 2020 -27.74M
December 31, 2019 -32.14M
September 30, 2019 -27.15M
June 30, 2019 -33.40M
March 31, 2019 -43.23M
December 31, 2018 -37.36M
September 30, 2018 -28.82M
June 30, 2018 -28.17M
March 31, 2018 -29.89M
December 31, 2017 -33.88M
September 30, 2017 -22.01M
June 30, 2017 -23.56M
March 31, 2017 -24.69M
December 31, 2016 -24.20M
September 30, 2016 -8.744M
June 30, 2016 -12.44M
March 31, 2016 -3.609M
December 31, 2015 12.33M
September 30, 2015 52.90M
June 30, 2015 -16.52M
March 31, 2015 -13.04M
December 31, 2014 -9.05M
September 30, 2014 -6.637M
June 30, 2014 -13.65M
March 31, 2014 9.479M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Geron Corp. -15.83M
Neurocrine Biosciences, Inc. 78.00M
Elicio Therapeutics, Inc. -8.165M
Agenus, Inc. -31.20M
Amgen, Inc. 4.002B